louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03518190: Early Detection of Pressure Induced Tissue Damage by Infrared Spectroscopy (ODP) Device
Official title: Early Detection of Pressure Induced Tissue Damage by Infrared Spectroscopy (ODP) Device
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pressure Ulcer Not Visible
Lead sponsor: Rambam Health Care Campus
Sponsor class: OTHER
First posted: 2018-05-08
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: The aim of this study is to demonstrate that infrared spectroscopy is able to detect pressure injuries at a very early stage

Detailed description: During pressure injuries formation early sub dermal bio signal appear. By applying infrared spectroscopy at a suspicions injury site on the human body and obtaining a reflected infrared light infrared allows to determine early formation of a pressure injury/

Eligibility criteria: Inclusion Criteria:

* Patients with stage 1 pressure injury
* Patients with high risk of developing pressure injury

Exclusion Criteria:

* Patients with stage 2 pressure injury or higher

Primary outcomes:
measure: Early detection of pressure induced tissue damage
timeFrame: Ten minutes
measure: Pressure injury probability
timeFrame: Ten minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Haifa
country: Israel
facility: Rambam healrh care campus
Study officials:
References:
Clinical trial NCT00742690: Terlipressin Given As I.V. Boluses Versus Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome
Official title: Terlipressin Given As I.V. Boluses Vs Terlipressin Given As Continuous Intravenous Infusion In Patients With Cirrhosis And Type 1 Hepatorenal Syndrome (Hrs): Preliminary Results Of A Randomized Controlled Clinical Study.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE2
PHASE3
Conditions: Cirrhosis
Type 1 Hepatorenal Syndrome
Keywords: cirrhosis
type 1 hepatorenal syndrome
terlipressin
albumin
effective circulating volume
Patients
with
Lead sponsor: University of Padova
Sponsor class: OTHER
First posted: 2008-08-28
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: It is well known that terlipressin and albumin improve renal function in patients with cirrhosis and type 1 HRS. In previous studies terlipressin has been used either as intravenous boluses moving from an initial dose of 0.5-1 mg/4 hr or as continuous intravenous infusion at the initial dose of 2 mg/24 h. Up to now the two schedules of i.v. administration of terlipressin have never been compared. Nevertheless, it has been hypothesized that continuous intravenous infusion assures a more steady profile of effect on portal pressure in patients with cirrhosis. Thus, the aim of the study will be to compare terlipressin given as i.v. bolus vs terlipressin given as continuous intravenous infusion in the treatment of type 1 HRS in patients with cirrhosis.


Eligibility criteria: Inclusion Criteria:

* Patients with cirrhosis and type 1 HRS

Exclusion Criteria:

* HCC beyond the Milan Criteria,septic shock (systolic arterial pressure \< 90 mmHg,
* Significant heart or respiratory failure,
* Peripheral arteriophaty clinically significant,
* Previous heart stroke or significant alteration of the ECG

Primary outcomes:
measure: The primary end-point of the study is the complete reform of the renal function (creatinine < 1.5 mg/dl).
timeFrame: The treatment will be continued for a maximum of 15 days
Secondary outcomes:
Other outcomes:
Locations:
city: Padova
country: Italy
facility: Liver Unit, General Hospital
Study officials:
References:
citation: Angeli P, Guarda S, Fasolato S, Miola E, Craighero R, Piccolo F, Antona C, Brollo L, Franchin M, Cillo U, Merkel C, Gatta A. Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost. Aliment Pharmacol Ther. 2006 Jan 1;23(1):75-84. doi: 10.1111/j.1365-2036.2006.02706.x.
Clinical trial NCT00792090: Prevention of Cow's Milk Allergy in Children
Official title: Use of Fermented Milk in Prevention of Cow's Milk Allergy in New Born and Infant
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Milk Hypersensitivity
Keywords: allergy
cow's milk
sensibilisation
fermented milk
infant formula
Lead sponsor: Bledina
Sponsor class: INDUSTRY
Collaborators: name: Optimed Medizinische Instrumente GmbH
First posted: 2008-11-17
Enrollment: 142
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Impact of fermented milk in prevention of cow's milk allergy in new born and infants


Eligibility criteria: Inclusion Criteria:

* mother before the 5th month of pregnancy
* mother agreeing to stop consumption of yogurts and fermented milks during the 3rd quarter of pregnancy
* mother agreeing to receive a calcium supplementation during the 3rd quarter of pregnancy
* atopic mother or father and at least another atopic member (sister or brother)
* parents having given written informed consent
* adhesion to eviction regimen for mother and child
* parents agreeing with a regular follow-up (3 visits and monthly phone call with the dietician)

Exclusion Criteria:

* mother in an exclusion period from another study
* parents refusing to sign the informed consent
* infant in a situation which could interfere with an optimal participation to the study, or which could represent a risk for the infant, according to the investigator
* known or suspected immunodeficiency in the family

Primary outcomes:
measure: Sensibilisation and cow's milk allergy
timeFrame: 4, 12 and 24 months
Secondary outcomes:
measure: Sensitization or allergy to other allergens
timeFrame: 4, 12 and 24 months
measure: Atopic diseases (atopic dermatitis, asthma)
timeFrame: 4, 12 and 24 months
Other outcomes:
Locations:
city: Nancy
country: France
facility: Hôpital central
city: Paris
country: France
facility: Hôpital Saint Vincent de Paul
Study officials:
affiliation: Hôpital Saint Vincent de Paul
name: Christophe Dupont, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Hôpital central
name: Denise-Anne Moneret-Vautrin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00654290: Effect of Prophylaxy of Amiodarone and Propranolol and Amiodarone With Propranolol in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft
Official title: Effect of Prophylaxy of Amiodarone and Propranolol and Amiodarone With Propranolol in Prevention of Atrial Fibrillation Post Coronary Artery Bypass Graft, A Prospective Double-Blind Randomized Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation
coronary bypass
Amiodarone
Propranolol
Coronary Artery Bypass Graft (CABG)
Lead sponsor: Shiraz University of Medical Sciences
Sponsor class: OTHER
First posted: 2008-04-07
Enrollment: 240
Sex: ALL
Minimum age (years): 45
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Atrial fibrillation is the most common arrhythmia post coronary bypass surgery, currently B-blockers are the class I indication to prevent AF post CABG. We decide to evaluate use of propranolol and amiodarone separately and together to find a better prophylaxis for AF peri-CABG

Detailed description: In this double blind randomized study 240 consecutive patients underwent elective coronary artery bypass grafting, being randomized prospectively into three groups, propranolol (p) (n=80), amiodarone (A) (n=80) and amiodarone with propranolol (AP) (n=80).

All groups received their medications from 7 days preoperatively and continued their medications for 5 days post CABG.

Eligibility criteria: Inclusion Criteria:

* Patient who are going to have elective CABG
* Signing informed consent

Exclusion Criteria:

* EF\<35%
* Bradycardia\<60 per min
* Hypotension\< 100 mmhg

Primary outcomes:
measure: incidence of atrial fibrillation post CABG
timeFrame: 7 days post CABG
Secondary outcomes:
measure: bradycardia, mortality, hypotension, morbidity
timeFrame: 7 days post CABG
Other outcomes:
Locations:
city: Shiraz
country: Iran, Islamic Republic of
facility: Shiraz University of Medical Sciences/Cardiac Surgery and Cardiology Ward/Namazi and Shahid Faghihi Hospital
state: Fars
Study officials:
References:
citation: Kojuri J, Mahmoodi Y, Jannati M, Shafa M, Ghazinoor M, Sharifkazemi MB. Ability of amiodarone and propranolol alone or in combination to prevent post-coronary bypass atrial fibrillation. Cardiovasc Ther. 2009 Winter;27(4):253-8. doi: 10.1111/j.1755-5922.2009.00100.x.
Clinical trial NCT03697590: Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage
Official title: Photodynamic Therapy of Actinic Keratosis of the Face and Scalp With and Without Prior Curettage
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Keratosis, Actinic
Lead sponsor: Bispebjerg Hospital
Sponsor class: OTHER
First posted: 2018-10-05
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Guidelines for photodynamic therapy (PDT) of actinic keratosis recommend pretreatment with curettage. The impact of curettage on the treatment effect is, however, not known. The present study aimed to evaluate whether daylight-PDT without curettage would reduce treatment effect compared to daylight-PDT with curettage.


Eligibility criteria: Inclusion Criteria:

- Multiple actinic keratosis on the forehead or scalp

Exclusion Criteria:

* Known allergy to methyl aminolevulinate
* Porphyria
* Pregnancy
* Lactation

Primary outcomes:
measure: Complete lesion response rate
timeFrame: Treatment efficacy was evaluated 3 months after PDT
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen NV
country: Denmark
facility: Bispebjerg Hospital
state: DK
Study officials:
References:
Clinical trial NCT00629590: Safety and Efficacy Pilot Study of AzaSite (Azithromycin) in Subjects With Blepharitis
Official title: A Single-Center, Open-Label, Randomized Pilot Study of the Safety and Efficacy of AzaSite® Ophthalmic Solution, 1% in Combination With Mechanical Therapy Versus Mechanical Therapy Alone for Two Weeks in Subjects With Posterior Blepharitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Blepharitis
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2008-03-06
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the safety and efficacy of AzaSite ophthalmic solution, 1% on signs and symptoms of blepharitis.


Eligibility criteria: Inclusion Criteria:

* diagnosis of moderate to severe chronic posterior blepharitis
* if female of childbearing potential, are non-pregnant and non-lactating

Exclusion Criteria:

* had ocular surface surgery (LASIK, refractive, etc.) within the past year
* unwilling to discontinue use of contact lenses during the study
* have glaucoma
* unable or unwilling to withhold the use of lid scrubs during the study
* have a serious systemic disease or uncontrolled medical condition that in the judgment of the investigator could confound study assessments or limit compliance
* currently using any preserved topical ocular medications (with the exception of unpreserved tear substitutes) at the time of entry into the study or during study participation

Primary outcomes:
measure: Change in clinical signs and symptoms associated with blepharitis
timeFrame: 2 weeks
Secondary outcomes:
measure: Standard ocular safety assessments
timeFrame: 2 weeks
Other outcomes:
Locations:
city: Wantagh
country: United States
facility: South Shore Eye Care
state: New York
Study officials:
affiliation: works for Sponsor
name: Reza Haque
role: STUDY_DIRECTOR
References:
Clinical trial NCT01517490: Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes
Official title: Retinal Adaptation to Intensified Insulin Therapy and Bariatric Surgery in Patients With Diabetes
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diabetes Mellitus
Diabetic Retinopathy
Lead sponsor: Glostrup University Hospital, Copenhagen
Sponsor class: OTHER
First posted: 2012-01-25
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 30 patients with type 1 diabetes and suboptimal metabolic regulation which is to be optimized by insulin pump therapy.

30 patients with type 1 diabetes and suboptimal metabolic regulation in whom insulin pump therapy is not planned.

20 patients with type 2 diabetes and suboptimal metabolic regulation who are enrolled in a pre-operative weight lowering protocol prior to bariatric surgery.

20 patients with type 2 diabetes and suboptimal metabolic regulation who are not enrolled in treatment protocols relating to bariatric surgery.

17 patients with type 1 diabetes on insulin pump therapy who were previously followed in an observational study of retinal function.

Brief summary: Retinal function is highly dependent on the glucose supply. Thus, functional adaptations occur in response to both acute and long-term changes in glycaemia.

The purpose of this study is to examine functional and metabolic aspects of retinal adaptation to long-lasting changes in glycaemic control in patients with diabetes. The adaptational phenomena will be characterized by electroretinography, dark adaptation, measures of retinal perfusion and oximetry as well as diabetic retinopathy grading and (OCT).


Eligibility criteria: Inclusion Criteria:

* Patients with type 1 diabetes and suboptimal metabolic regulation.
* Patients with type 2 diabetes and suboptimal metabolic regulation.

Exclusion Criteria:

* Significant cataract
* Glaucoma
* Proliferative diabetic retinopathy fulfilling ETDRS treatment criteria.
* Clinically significant macular edema fulfilling ETDRS treatment criteria.
* Age-related macular degeneration
* Prior surgery to the eye
* Other serious eye disease
* Hypertension

Primary outcomes:
measure: Changes in dark adaptation kinetics and threshold values, amplitudes/implicit times, retinal vessel diameters, perfusion velocity and oximetry.
timeFrame: Baseline, 1 week, 1 month, 4 months, 7 months, 12 months, 18 months, 24 months, 42 months
measure: Changes in visual acuity, diabetic retinopathy grading and OCT
timeFrame: Baseline, 1 week, 1 month, 4 months, 7 months, 12 months, 18 months, 24 months, 42 months
Secondary outcomes:
Other outcomes:
Locations:
city: Glostrup
country: Denmark
facility: Department of Ophthalmology, Glostrup Hospital
Study officials:
affiliation: Glostrup UH
name: Oliver Klefter, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Glostrup UH
name: Michael Larsen, Professor, DMSci
role: STUDY_DIRECTOR
References:
Clinical trial NCT01497990: Pharmacokinetics Ertapenem Burns
Official title: Pharmacokinetics of Ertapenem When Used in Empiric Treatment in Burn Patients. Prospective Open Label Study.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Burn Patients
Keywords: Burns
Ertapenem
Pharmacokinetics
Lead sponsor: Nantes University Hospital
Sponsor class: OTHER
First posted: 2011-12-23
Enrollment: 8
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will examine the pharmacokinetics of ertapenem in ventilated badly (\> 30% SCT) burn patients.


Eligibility criteria: Inclusion Criteria:

* Patients aged 18 to 70 years
* Burned on 30 to 60% of their body surface
* Mechanical ventilation
* Hospitalized in the intensive care unit of Nantes University Hospital for less than 8 days.
* Which the family gave consent
* insured

Exclusion Criteria:

* Patients whose family refused to sign the consent for participation.
* Patients allergic to beta lactam
* Patients with renal failure with creatinine clearance \<80 ml.mn-1
* Pregnant women
* Persons protected by the law

Primary outcomes:
measure: Measurement of serum concentrations of total ertapenem from the second injection in order to calculate Cmax, Vz, ClP , ClR , ClNR , fe, T1/2b et AUC0 - alpha.
timeFrame: Blood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injection
Secondary outcomes:
measure: Time between injection and observation of a serum concentration less than the critical concentration below
timeFrame: Blood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injection
measure: Time needed between injections in order to obtain a concentration greater than the critical concentration below for the duration of time between two injections
timeFrame: Blood samples 5 min after the end of the second injection and 1 h, 2 h, 4 h, 6 h, 8 h, 12 h, 24 h after the start of the second injection
Other outcomes:
Locations:
city: Nantes
country: France
facility: Nantes University Hospital
Study officials:
affiliation: Nantes University Hospital
name: Ronan LE FLOCH, PH
role: STUDY_CHAIR
References:
Clinical trial NCT04357990: Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19
Official title: Use of a Medical Device, Viruxal Oral and Nasal Spray, for Treating the Symptoms of COVID-19 Via Application to the Naso- and Oropharyngeal Mucosa
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19
Lead sponsor: Kerecis Ltd.
Sponsor class: INDUSTRY
First posted: 2020-04-22
Enrollment: 128
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf (the "Device"). A double blind clinical trial will be conducted to evaluate the Device against placebo in COVID-19 positive, symptomatic patients in Iceland. Immediate access to COVID-19 patients is available through a well-organized COVID-19 outpatient follow-up clinic. Up to 128 patients with mild to moderate symptoms of COVID-19 will be recruited (so called "higher end of the low risk group"). These patients will be positive for COVID-19, be symptomatic with upper respiratory symptoms, but without involvement of the entire respiratory system. The patients will be randomized to receive treatment with the Study Device or to receive placebo. 64 patients will be randomized into the Study Device group and 64 patients into the Control group. Patients will administer Study Device or Control for 14 days and will have their symptoms recorded until no further symptoms are reported, up to a maximum of 28 days follow-up.


Eligibility criteria: Inclusion Criteria:

* ≥18 years of age
* Positive for SARS-CoV-2 infection
* Has symptoms of upper respiratory infection
* Willing to participate in the clinical trial and gives consent
* Is not pregnant, nor actively trying to conceive a child.

Exclusion Criteria:

* Under 18 years of age
* Negative for SARS-CoV-2 infection
* Severe symptoms of infection
* Symptoms involving the entire respiratory system, including Pneumonia
* Requires hospitalisation prior to study start
* Asymptomatic
* Pregnant or actively trying to conceive a child
* Other comorbidities that would prevent administration of the device
* Requirement to take regular medications administered by inhalation, or via the naso- and oropharyngeal route
* Patients with known allergies to Neem or Hypericum oil
* Patients with asthma

Primary outcomes:
measure: Number of days until complete resolution of symptoms per group
timeFrame: 28 days
measure: Number of hospital admissions per group
timeFrame: 28 days
Secondary outcomes:
measure: Number of days until a reduction in symptoms per group
timeFrame: 28 days
measure: Number of adverse events per group
timeFrame: 28 days
Other outcomes:
Locations:
city: Reykjavík
country: Iceland
facility: National Hospital of Iceland (Landspítali)
Study officials:
affiliation: Landspitalinn University Hospital, Iceland
name: Ragnar F Ingvarsson, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01391390: Melatonin Treatment for Tardive Dyskinesia in Schizophrenia
Official title: The Effect of Melatonin Treatment on Tardive Dyskinesia and Oxidative Stress: A Double-Blind Placebo-Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Tardive Dyskinesia
Keywords: Tardive Dyskinesia
Schizophrenia
Melatonin
Oxidative Stress
Antioxidant
Lead sponsor: Beijing HuiLongGuan Hospital
Sponsor class: OTHER
Collaborators: name: Stanley Medical Research Institute
First posted: 2011-07-12
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a double-blind, randomized, placebo-controlled trial of melatonin as an add-on therapy to antipsychotics will be performed to examine the effects of melatonin on tardive dyskinesia symptoms and cognitive deficits in 120 patients with established tardive dyskinesia (TD). This study addresses a free radical hypothesis of TD.

Detailed description: 1. Since it has been proposed that neuroleptic-induced increases in free-radical production may relate to the development of TD, the investigators hypothesize that melatonin, an effective antioxidant, may attenuate the severity of tardive dyskinesia symptoms.
2. Due to increased cognitive deficits in patients with TD and implication of oxidative stress in cognitive impairment, the investigators hypothesize that both cognitive impairment and tardive dyskinesia symptoms may be induced by the same pathophysiological stimulus--oxidative stress. Hence, the investigators further hypothesize that both tardive dyskinesia symptoms and cognitive deficits in patients with TD may be improved by melatonin simultaneously.

Eligibility criteria: Inclusion Criteria:

1. diagnosis of both schizophrenia and TD;
2. duration of TD symptoms longer than 1 year;
3. on stable doses of antipsychotic drug for at least 6 months;
4. between 18 and 70 years of age.

Exclusion Criteria:

1. comorbid neurological illness other than TD;
2. if they have received vitamin C or vitamin E within 1 month before the start of the study;
3. alcohol/drug abuse;
4. acute, unstable medical condition;
5. pregnant or breastfeeding female;
6. use of other antioxidants.

Primary outcomes:
measure: the Abnormal Involuntary Movement Scale (AIMS)
timeFrame: 12 weeks
Secondary outcomes:
measure: the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)
timeFrame: 12 weeks
measure: the Positive and Negative Syndrome Scale (PANSS)
timeFrame: 12 weeks
measure: the Simpson-Angus Scale for extrapyramidal side effects (SAS)
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Beijing
country: China
facility: Beijing HuiLongGuan hospital
Study officials:
affiliation: Beijing HuiLongGuan Hospital
name: Lian Y Cao, MD
role: STUDY_CHAIR
References: